Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933653 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2725094 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL3398592 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL21821171 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2745077 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL18498060 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL18498063 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL3392372 | 0.75 | MAPT (0.34) | — | |
| SCHEMBL13000960 | 0.75 | MAPT (0.34) | — | |
| SCHEMBL28332968 | 0.74 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-4139302-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2021216949-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1521747-A4 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1521747-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004006846-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | CHRNB2 2734/4885CHRNB4 1736/4885CHRNA3 1528/4885 |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | CHRNB2 21/4885CHRNB4 18/4885CHRNA3 12/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | CHRNB2 23/4885CHRNB4 18/4885CHRNA3 10/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | CHRNB2 23/4885CHRNB4 17/4885CHRNA3 10/4885 |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | CHRNB2 2555/4885CHRNB4 2431/4885CHRNA3 2751/4885 |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRNB2 21/4885CHRNB4 18/4885CHRNA3 12/4885 |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | CHRNB2 21/4885CHRNB4 18/4885CHRNA3 12/4885 |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRNB2 21/4885CHRNB4 18/4885CHRNA3 12/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | CHRNB2 3429/4885CHRNB4 2492/4885CHRNA3 2396/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | CHRNB2 3429/4885CHRNB4 2492/4885CHRNA3 2396/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | CHRNB2 2734/4885CHRNB4 1736/4885CHRNA3 1528/4885 |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | CHRNB2 3505/4885CHRNB4 3146/4885CHRNA3 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.